Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

被引:118
作者
Pfeil, Alena M. [1 ]
Allcott, Kim [2 ]
Pettengell, Ruth [3 ]
von Minckwitz, Gunter [4 ,5 ]
Schwenkglenks, Matthias [1 ]
Szabo, Zsolt [6 ]
机构
[1] Univ Basel, Inst Pharmaceut Med, CH-4056 Basel, Switzerland
[2] Oxford PharmaGenesis Ltd, Oxford, England
[3] St Georges Univ London, London, England
[4] German Breast Grp, Neu Isenburg, Germany
[5] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[6] Amgen Europe GmbH, Clin Dev, Zug, Switzerland
关键词
Balugrastim; Granulocyte colony-stimulating factor; Lipegfilgrastim; Neutropenia; Pegfilgrastim; Systematic review; SINGLE-ADMINISTRATION PEGFILGRASTIM; PATIENTS RECEIVING CHEMOTHERAPY; ALBUMIN-BOUND PACLITAXEL; FEBRILE NEUTROPENIA; BREAST-CANCER; DAILY FILGRASTIM; PHASE-II; DARBEPOETIN-ALPHA; LYMPHOMA PATIENTS; DOSE INTENSITY;
D O I
10.1007/s00520-014-2457-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating factors (G-CSFs) have recently been developed. We systematically reviewed the efficacy, effectiveness and safety of neutropenia prophylaxis with long-acting G-CSFs in cancer patients receiving chemotherapy. We performed a systematic literature search of the MEDLINE, EMBASE and Cochrane Library databases, and abstracts from key congresses. Studies of long-acting G-CSFs for prophylaxis of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) were identified by two independent reviewers. Abstracts and full texts were assessed for final inclusion; risk of bias was evaluated using the Cochrane's tool. Effectiveness and safety results were extracted according to study type and G-CSF used. Of the 839 articles identified, 41 articles representing different studies met the eligibility criteria. In five randomised controlled trials, 11 clinical trials and 17 observational studies across several tumour types and chemotherapy regimens, pegfilgrastim was used alone or compared with daily G-CSF, no G-CSF, no upfront pegfilgrastim or placebo. Studies generally reported lower incidence of CIN (4/7 studies), FN (11/14 studies), hospitalisations (9/13 studies), antibiotic use (6/7 studies) and adverse events (2/5 studies) with pegfilgrastim than filgrastim, no upfront pegfilgrastim or no G-CSF. Eight studies evaluated other long-acting G-CSFs; most (5/8) were compared to pegfilgrastim and involved patients with breast cancer receiving docetaxel-based therapy. Efficacy and safety profiles of balugrastim and lipegfilgrastim were comparable to pegfilgrastim in phase 3 studies. Efficacy and safety of other long-acting G-CSFs were mixed. Pegfilgrastim reduced the incidence of FN and CIN compared with no prophylaxis. Most studies showed better efficacy and effectiveness for pegfilgrastim than filgrastim. Efficacy and safety profiles of lipegfilgrastim and balugrastim were similar to pegfilgrastim.
引用
收藏
页码:525 / 545
页数:21
相关论文
共 66 条
[1]
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [J].
Aapro, M. S. ;
Bohlius, J. ;
Cameron, D. A. ;
Dal Lago, Lissandra ;
Donnelly, J. Peter ;
Kearney, N. ;
Lyman, G. H. ;
Pettengell, R. ;
Tjan-Heijnen, V. C. ;
Walewski, J. ;
Weber, Damien C. ;
Zielinski, C. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) :8-32
[2]
Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice [J].
Almenar Cubells, D. ;
Bosch Roig, C. ;
Jimenez Orozco, E. ;
Alvarez, R. ;
Cuervo, J. M. ;
Diaz Fernandez, N. ;
Sanchez Heras, A. B. ;
Galan Brotons, A. ;
Giner Marco, V. ;
De Villena, M. Codes M. .
EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (03) :400-412
[3]
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study [J].
Almenar, D. ;
Mayans, J. ;
Juan, O. ;
Garcia, Bueno J. M. ;
Jalon, Lopez J., I ;
Frau, A. ;
Guinot, M. ;
Cerezuela, P. ;
Garcia, Buscalla E. ;
Gasquet, J. A. ;
Sanchez, J. .
EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (03) :280-286
[4]
Daily G-CSFs versus pegfilgrastim (PEG) in cancer patients (pts) undergoing chemotherapy (CT): A multivariate analysis from clinical practice. [J].
Almenar-Cubells, D. ;
Roig, C. B. ;
Jimenez, E. ;
Cruz, M. A. ;
Cuervo, J. M. ;
Diaz, N. ;
Sanchez, A. B. ;
Galan, A. ;
Giner, V. ;
Codes, M. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5]
[Anonymous], SUPPORT CARE CANC OF
[6]
[Anonymous], J CLIN ONCOL OFF J A
[7]
[Anonymous], J CLIN ONCOL OFF J S
[8]
[Anonymous], HAEMATOL HEMATOL S2
[9]
[Anonymous], J CLIN ONCOL OFF J S
[10]
[Anonymous], ANN ONCOL OFF J EUR